SCHEMBL1746699

SCHEMBL1746699

CCCCCCCCCCCCCCCCCCCCCCCC(=O)NCCc1c[nH]c2ccc(O)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 11/20 1.00
FAAH O00519 1/20 0.79
PTGS2 P35354 1/20 0.79
MTNR1A P48039 4/20 0.73
SPR P35270 3/20 0.67
MTNR1B P49286 2/20 0.67
KDM4E B2RXH2 1/20 0.67
ALDH1A1 P00352 1/20 0.67
CYP1A2 P05177 1/20 0.67
CYP3A4 P08684 1/20 0.67
CYP2D6 P10635 1/20 0.67
MAPT P10636 1/20 0.67
IDO1 P14902 1/20 0.67
HPGD P15428 1/20 0.67
BLM P54132 1/20 0.67
NOTUM Q6P988 1/20 0.67
NPSR1 Q6W5P4 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1129798 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL23630270 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL23630280 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL3815737 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL23630267 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL23630266 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL23643317 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL23630276 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL23630268 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR
SCHEMBL1746356 1.00 TRPV1 (1.00) TRPV1FAAHPTGS2MTNR1ASPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210369720-A1 SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2021-12-02 US disclosed
EP-3207029-B1 TRYPTAMIDE COMPOSITIONS AND METHODS OF USE SIGNUM BIOSCIENCES INC (US) 2021-08-04 EP disclosed
US-10314817-B2 Tryptamide compositions and methods of use SIGNUM BIOSCIENCES, INC. (US) 2019-06-11 US disclosed
EP-3207029-A1 TRYPTAMIDE COMPOSITIONS AND METHODS OF USE Signum Biosciences, Inc. (US) 2017-08-23 EP disclosed
US-20170231955-A1 TRYPTAMIDE COMPOSITIONS AND METHODS OF USE SIGNUM BIOSCIENCES, INC. 2017-08-17 US disclosed
WO-2016061357-A1 TRYPTAMIDE COMPOSITIONS AND METHODS OF USE SIGNUM BIOSCIENCES, INC. (US) 2016-04-21 WO disclosed
EP-2467026-B1 HEALTHY COFFEE AND METHODS OF ITS PRODUCTION TCHIBO GMBH (DE) 2013-10-23 EP disclosed
US-8524307-B2 Healthy coffee and methods of its production TCHIBO GMBH (DE) 2013-09-03 US disclosed
US-20130156928-A1 HEALTHY COFFEE AND METHODS OF ITS PRODUCTION TCHIBO GMBH (DE) 2013-06-20 US disclosed
EP-2467026-A1 HEALTHY COFFEE AND METHODS OF ITS PRODUCTION Tchibo GmbH (DE) 2012-06-27 EP disclosed
WO-2011134656-A1 HEALTHY COFFEE AND METHODS OF ITS PRODUCTION TCHIBO GMBH (DE) 2011-11-03 WO disclosed
EP-2382868-A1 Healthy coffee and method of its production Tchibo GmbH (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10314817-B2 Tryptamide compositions and methods of use HNMT, TPH2, TPH1 TRPV1 880/4885FAAH 37/4885PTGS2 738/4885
US-20170231955-A1 TRYPTAMIDE COMPOSITIONS AND METHODS OF USE HNMT, TPH2, TPH1 TRPV1 880/4885FAAH 37/4885PTGS2 738/4885
US-20210369720-A1 SYNERGISTIC COMPOSITION HAVING NEUROPROTECTIVE PROPERTIES AND METHODS OF USE THEREOF BDNF, TPH2, TPH1 TRPV1 1255/4885FAAH 20/4885PTGS2 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.